MAPK3 and Parkinson disease: GPS (25 and 50 mg/kg) and GPE (50 mg/kg) could effectively attenuate the development of L-DOPA-induced-dyskinesia without compromising the anti-Parkinson effects of L-DOPA by reducing ΔFosB expression and ERK1/2 phosphorylation in the 6-hydroxydopamine (6-OHDA)-lesioned rat model of PD [92].